Literature DB >> 2918766

Bug/drug resistance. Sometimes less is more.

C E Phelps1.   

Abstract

Increased use of antibiotics in any community increases the risks that future bacterial strains will resist the effects of current antibiotics. The consequences of a resistant bacterial strain include costs for more expensive and powerful drugs, additional hospital days, and on rare occasion, death. A key to understanding the importance of this problem is better knowledge about the rate that resistance increases and persists as antibiotic use rates increase. Using the scant evidence available in the literature, this study conducts a sensitivity analysis to calculate the unrecognized costs of antibiotic use annually in the United States under various possible circumstances. For the estimated 150 million annual antibiotic prescriptions, the unrecognized costs appears to be at least $.1 billion, and they may exceed $30 billion in the worst case. The estimates of the burden caused by bacterial resistance to antibiotics depend heavily on unknown parameters, including the rate that resistance occurs, the dose-resistance patterns through time, the frequency of inappropriate use of antibiotics, and the frequency with which death occurs due to a resistant bacterial infection. New studies in each of these areas are needed to improve our understanding of the extent of the resistance problem.

Entities:  

Mesh:

Year:  1989        PMID: 2918766

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  20 in total

1.  Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam.

Authors:  Y Carmeli; J Castro; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Measuring the externality of antibacterial use from promoting antimicrobial resistance.

Authors:  Klaus Kaier; Uwe Frank
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note.

Authors:  Klaus Kaier; Uwe Frank
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

Review 4.  Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe.

Authors:  W T M Jansen; J T van der Bruggen; J Verhoef; A C Fluit
Journal:  Drug Resist Updat       Date:  2006-06-27       Impact factor: 18.500

5.  Assessing antibacterial pharmacoeconomics in the intensive care unit.

Authors:  M C Birmingham; J M Hassett; J J Schentag; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

6.  Is nationwide special campaign on antibiotic stewardship program effective on ameliorating irrational antibiotic use in China? Study on the antibiotic use of specialized hospitals in China in 2011-2012.

Authors:  Xiao-Xu Zou; Zi Fang; Rui Min; Xue Bai; Yang Zhang; Dong Xu; Peng-Qian Fang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

7.  Evaluation of ceftriaxone utilization at multicenter study.

Authors:  Hyuck Lee; Dongsik Jung; Joon Sup Yeom; Jun Seong Son; Sook-In Jung; Yeon-Sook Kim; Chun Kwan Kim; Hyun-Ha Chang; Shin-Woo Kim; Hyun Kyun Ki; Chi Sook Moon; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song; Gun-Jo Woo
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

8.  Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults.

Authors:  Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Michael J Fine; Kenneth J Smith
Journal:  J Gen Intern Med       Date:  2014-04       Impact factor: 5.128

9.  Silver-doped bioactive glass particles for in vivo bone tissue regeneration and enhanced methicillin-resistant Staphylococcus aureus (MRSA) inhibition.

Authors:  Natalia Pajares-Chamorro; Yadav Wagley; Chima V Maduka; Daniel W Youngstrom; Alyssa Yeger; Stephen F Badylak; Neal D Hammer; Kurt Hankenson; Xanthippi Chatzistavrou
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2020-11-05       Impact factor: 7.328

10.  The Use of an Organo-Selenium Peptide to Develop New Antimicrobials That Target a Specific Bacteria.

Authors:  Phat Tran; Jonathan Kopel; Joe A Fralick; Ted W Reid
Journal:  Antibiotics (Basel)       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.